{"id":"pb-201","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL503722","moleculeType":"Small molecule","molecularWeight":"1147.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a product from PegBio Co., Ltd., PB-201 likely leverages PEGylation technology to improve pharmacokinetic properties of a biologic molecule. The specific mechanism depends on its molecular target, which is not publicly disclosed in available sources. Further clinical data from Phase 3 trials would clarify its precise mechanism of action.","oneSentence":"PB-201 is a PEGylated biologic therapeutic designed to modulate immune function or target a specific disease pathway.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:57.065Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05326490","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2022-05-30","conditions":"Type 2 Diabetes Mellitus","enrollment":546},{"nctId":"NCT05102149","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2021-09-30","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":672},{"nctId":"NCT03973515","phase":"PHASE1","title":"Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"PegBio Co., Ltd.","startDate":"2019-08-27","conditions":"Type2 Diabetes Mellitus","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PB-201","genericName":"PB-201","companyName":"PegBio Co., Ltd.","companyId":"pegbio-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}